SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm (NASDAQ:FLDM) today introduced Helios, a CyTOF platform that enables system-level biology at single-cell resolution, on an accessible, expandable system designed for breakthrough discovery.